Evidence map›Paper›PMID 40610024›Full record

ArticleClinical & experimental ophthalmology2025

Proposal of a Simpler Eye-Level Risk Model Incorporating Reticular Pseudodrusen for the Clinical Prediction of Late Age-Related Macular Degeneration.

Matt Trinh, Annita Duong, Rene Cheung, Simon Chen, David Ng, Jeff Friedrich, Chris Hodge, Lisa Nivison-Smith, Angelica Ly

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical & experimental ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Matt TrinhSchool of Optometry and Vision Science, University of New South Wales, Sydney, New South Wales, Australia.ORCID 0000-0002-6184-0666
Annita DuongSchool of Optometry and Vision Science, University of New South Wales, Sydney, New South Wales, Australia.
Rene CheungSchool of Optometry and Vision Science, University of New South Wales, Sydney, New South Wales, Australia.
Simon ChenSchool of Optometry and Vision Science, University of New South Wales, Sydney, New South Wales, Australia.
David NgVision Eye Institute, Sydney, New South Wales, Australia.
Jeff FriedrichVision Eye Institute, Sydney, New South Wales, Australia.
Chris HodgeVision Eye Institute, Sydney, New South Wales, Australia.
Lisa Nivison-SmithSchool of Optometry and Vision Science, University of New South Wales, Sydney, New South Wales, Australia.
Angelica LySchool of Optometry and Vision Science, University of New South Wales, Sydney, New South Wales, Australia.

Funding

Future Vision Foundation
6 · The paper itself

Abstract

backgroundThe updated simplified AREDS risk model predicts progression to late age-related macular degeneration (AMD) by person, describing up to nine observations across both eyes and 10 annual risk scores (0-4, with/without reticular pseudodrusen [RPD]). This study proposes an abridged model to enable inter-eye comparisons and potentially enhance clinical efficiency.

methodsThis retrospective cohort study included 269 participants with early/intermediate AMD over 7 years. The full, person-level updated simplified AREDS risk model was compared to eye-level candidate risk models, derived by removing the least predictive biomarkers. The main outcomes were prognostic performance (AUC) and risk score separability (χ

resultsAt 1-3 years, the full model showed prognostic performance (AUC ± SE) up to 84.52% ± 5.93%, with overlap between most risk scores (χ

conclusionsThe updated simplified AREDS risk model can be essentially halved without compromising prognostic performance by deriving eye-specific biomarkers and assigning one point per biomarker (large drusen, pigmentary abnormalities, and RPD in the primary eye, and late AMD in the fellow eye). This eye-level risk stratification may improve clinical efficiency and inter-eye study designs when one eye is of particular interest. An example of 3-year risks (scores 0-4) was ≈4%, 8%, 16%, 32%, and 64%.

Indexed as

Macular DegenerationRetinal DrusenAgedAged, 80 and overDisease ProgressionFemaleFluorescein AngiographyFollow-Up StudiesHumansMaleMiddle AgedPrognosisRetrospective StudiesRisk AssessmentRisk FactorsTomography, Optical Coherenceage‐related macular degenerationclinicalpredictionprognosisreticular pseudodrusenrisk

Identifiers

PMID40610024
PMCPMC12596412

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.